{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:45:15Z","timestamp":1782909915616,"version":"3.54.5"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Intrahepatic cholangiocarcinoma (ICC) is the second most common malignancy among primary liver cancers, with an increasing overall incidence and poor prognosis. The intertumoral and intratumoral heterogeneity of ICC makes it difficult to find efficient drug therapies. Therefore, it is essential to identify tumor suppressor genes and oncogenes that induce ICC formation and progression. Here, we performed CRISPR\/Cas9-mediated genome-wide screening in a liver-specific Smad4\/Pten knockout mouse model (<jats:italic>Smad4<\/jats:italic><jats:sup><jats:italic>co\/co<\/jats:italic><\/jats:sup><jats:italic>;Pten<\/jats:italic><jats:sup><jats:italic>co\/co<\/jats:italic><\/jats:sup><jats:italic>;Alb-Cre<\/jats:italic>, abbreviated as SPC), which normally generates ICC after 6 months, and detected that mutations in <jats:italic>Trp53<\/jats:italic>, <jats:italic>Fbxw7<\/jats:italic>, <jats:italic>Inppl1<\/jats:italic>, <jats:italic>Tgfbr2<\/jats:italic>, or <jats:italic>Cul3<\/jats:italic> markedly accelerated ICC formation. To illustrate the potential mechanisms, we conducted transcriptome sequencing and found that multiple receptor tyrosine kinases were activated, which mainly upregulated the PI3K pathway to induce cell proliferation. Remarkably, the <jats:italic>Cul3<\/jats:italic> mutation stimulated cancer progression mainly by altering the immune microenvironment, whereas other mutations promoted the cell cycle. Moreover, Fbxw7, Inppl1, Tgfbr2, and Trp53 also affect inflammatory responses, apelin signaling, mitotic spindles, ribosome biogenesis, and nucleocytoplasmic transport pathways, respectively. We further examined FDA-approved drugs for the treatment of liver cancer and performed high-throughput drug screening of the gene-mutant organoids. Different drug responses and promising drug therapies, including chemotherapy and targeted drugs, have been discovered for ICC.<\/jats:p>","DOI":"10.1038\/s41419-023-06406-7","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T16:02:29Z","timestamp":1704988949000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The heterogeneity of signaling pathways and drug responses in intrahepatic cholangiocarcinoma with distinct genetic mutations"],"prefix":"10.1038","volume":"15","author":[{"given":"Yangyang","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh Haipeng","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7532-1680","authenticated-orcid":false,"given":"Jingbo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8033-3902","authenticated-orcid":false,"given":"Chu-Xia","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,11]]},"reference":[{"key":"6406_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"6406_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12253-018-0491-8","volume":"26","author":"G Lendvai","year":"2020","unstructured":"Lendvai G, Szekerczes T, Illyes I, Dora R, Kontsek E, Gogl A, et al. Cholangiocarcinoma: classification, histopathology and molecular carcinogenesis. Pathol Oncol Res. 2020;26:3\u201315.","journal-title":"Pathol Oncol Res"},{"key":"6406_CR3","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557\u201388.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"6406_CR4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","volume":"15","author":"S Rizvi","year":"2018","unstructured":"Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15:95\u2013111.","journal-title":"Nat Rev Clin Oncol"},{"key":"6406_CR5","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1245\/s10434-014-3828-x","volume":"21","author":"AX Zhu","year":"2014","unstructured":"Zhu AX, Borger DR, Kim Y, Cosgrove D, Ejaz A, Alexandrescu S, et al. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets. Ann Surg Oncol. 2014;21:3827\u201334.","journal-title":"Ann Surg Oncol"},{"key":"6406_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.7150\/ijbs.23230","volume":"14","author":"M Zhao","year":"2018","unstructured":"Zhao M, Mishra L, Deng CX. The role of TGF-beta\/SMAD4 signaling in cancer. Int J Biol Sci. 2018;14:111\u201323.","journal-title":"Int J Biol Sci"},{"key":"6406_CR7","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/s41580-018-0015-0","volume":"19","author":"YR Lee","year":"2018","unstructured":"Lee YR, Chen M, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor: new modes and prospects. Nat Rev Mol Cell Biol. 2018;19:547\u201362.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"6406_CR8","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1172\/JCI27282","volume":"116","author":"X Xu","year":"2006","unstructured":"Xu X, Kobayashi S, Qiao W, Li C, Xiao C, Radaeva S, et al. Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest. 2006;116:1843\u201352.","journal-title":"J Clin Invest"},{"key":"6406_CR9","doi-asserted-by":"publisher","first-page":"4176","DOI":"10.7150\/ijbs.67379","volume":"17","author":"M Zhao","year":"2021","unstructured":"Zhao M, Quan Y, Zeng J, Lyu X, Wang H, Lei JH, et al. Cullin3 deficiency shapes tumor microenvironment and promotes cholangiocarcinoma in liver-specific Smad4\/Pten mutant mice. Int J Biol Sci. 2021;17:4176\u201391.","journal-title":"Int J Biol Sci"},{"key":"6406_CR10","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/nprot.2016.174","volume":"12","author":"X Liu","year":"2017","unstructured":"Liu X, Krawczyk E, Suprynowicz FA, Palechor-Ceron N, Yuan H, Dakic A, et al. Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens. Nat Protoc. 2017;12:439\u201351.","journal-title":"Nat Protoc"},{"key":"6406_CR11","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.1231143","volume":"339","author":"L Cong","year":"2013","unstructured":"Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome engineering using CRISPR\/Cas systems. Science. 2013;339:819\u201323.","journal-title":"Science"},{"key":"6406_CR12","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nmeth.3047","volume":"11","author":"NE Sanjana","year":"2014","unstructured":"Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods. 2014;11:783\u20134.","journal-title":"Nat Methods"},{"key":"6406_CR13","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8:2281\u2013308.","journal-title":"Nat Protoc"},{"key":"6406_CR14","doi-asserted-by":"publisher","first-page":"9415","DOI":"10.7150\/thno.59533","volume":"11","author":"F Xing","year":"2021","unstructured":"Xing F, Liu YC, Huang S, Lyu X, Su SM, Chan UI, et al. Accelerating precision anti-cancer therapy by time-lapse and label-free 3D tumor slice culture platform. Theranostics. 2021;11:9415\u201330.","journal-title":"Theranostics"},{"key":"6406_CR15","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1093\/bioinformatics\/btw354","volume":"32","author":"P Ewels","year":"2016","unstructured":"Ewels P, Magnusson M, Lundin S, Kaller M. MultiQC: summarize analysis results for multiple tools and samples in a single report. Bioinformatics. 2016;32:3047\u20138.","journal-title":"Bioinformatics"},{"key":"6406_CR16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.3317","volume":"12","author":"D Kim","year":"2015","unstructured":"Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. Nat Methods. 2015;12:357\u201360.","journal-title":"Nat Methods"},{"key":"6406_CR17","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30:923\u201330.","journal-title":"Bioinformatics"},{"key":"6406_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"6406_CR19","first-page":"100141","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innov (Camb). 2021;2:100141.","journal-title":"Innov (Camb)"},{"key":"6406_CR20","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1053\/j.gastro.2012.02.009","volume":"142","author":"SF Katz","year":"2012","unstructured":"Katz SF, Lechel A, Obenauf AC, Begus-Nahrmann Y, Kraus JM, Hoffmann EM, et al. Disruption of Trp53 in livers of mice induces formation of carcinomas with bilineal differentiation. Gastroenterology. 2012;142:1229\u201339.e3.","journal-title":"Gastroenterology"},{"key":"6406_CR21","doi-asserted-by":"publisher","first-page":"5891","DOI":"10.1007\/s13277-015-3261-1","volume":"36","author":"TC Xue","year":"2015","unstructured":"Xue TC, Zhang BH, Ye SL, Ren ZG. Differentially expressed gene profiles of intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and combined hepatocellular-cholangiocarcinoma by integrated microarray analysis. Tumour Biol. 2015;36:5891\u20139.","journal-title":"Tumour Biol"},{"key":"6406_CR22","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.freeradbiomed.2023.04.021","volume":"204","author":"RJ Adamson","year":"2023","unstructured":"Adamson RJ, Payne NC, Bartual SG, Mazitschek R, Bullock AN. Structural and biochemical characterization establishes a detailed understanding of KEAP1-CUL3 complex assembly. Free Radic Biol Med. 2023;204:215\u201325.","journal-title":"Free Radic Biol Med"},{"key":"6406_CR23","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.semcancer.2019.03.003","volume":"59","author":"T Ijuin","year":"2019","unstructured":"Ijuin T. Phosphoinositide phosphatases in cancer cell dynamics-beyond PI3K and PTEN. Semin Cancer Biol. 2019;59:50\u201365.","journal-title":"Semin Cancer Biol"},{"key":"6406_CR24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrc.2017.104","volume":"18","author":"J Pelletier","year":"2018","unstructured":"Pelletier J, Thomas G, Volarevic S. Ribosome biogenesis in cancer: new players and therapeutic avenues. Nat Rev Cancer. 2018;18:51\u201363.","journal-title":"Nat Rev Cancer"},{"key":"6406_CR25","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1093\/annonc\/mdz394.031","volume":"30","author":"A Vogel","year":"2019","unstructured":"Vogel A, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. FIGHT-202: a phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA). Ann Oncol. 2019;30:876.","journal-title":"Ann Oncol"},{"key":"6406_CR26","doi-asserted-by":"crossref","unstructured":"Javle MM, Roychowdhury S, Kelley RK, Sadeghi S, Macarulla T, Waldschmidt DT, et al. Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement. J Clin Oncol. 2021;39:265.","DOI":"10.1200\/JCO.2021.39.3_suppl.265"},{"key":"6406_CR27","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21:796\u2013807.","journal-title":"Lancet Oncol"},{"key":"6406_CR28","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","volume":"7","author":"AX Zhu","year":"2021","unstructured":"Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol. 2021;7:1669\u201377.","journal-title":"JAMA Oncol"},{"key":"6406_CR29","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1053\/j.gastro.2013.01.001","volume":"144","author":"D Sia","year":"2013","unstructured":"Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology. 2013;144:829\u201340.","journal-title":"Gastroenterology"},{"key":"6406_CR30","doi-asserted-by":"publisher","first-page":"857140","DOI":"10.3389\/fmed.2022.857140","volume":"9","author":"T Chung","year":"2022","unstructured":"Chung T, Park YN. Up-to-date pathologic classification and molecular characteristics of intrahepatic cholangiocarcinoma. Front Med (Lausanne). 2022;9:857140.","journal-title":"Front Med (Lausanne)"},{"key":"6406_CR31","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.jhep.2019.05.027","volume":"71","author":"J Wang","year":"2019","unstructured":"Wang J, Wang H, Peters M, Ding N, Ribback S, Utpatel K, et al. Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis. J Hepatol. 2019;71:742\u201352.","journal-title":"J Hepatol"},{"key":"6406_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0857-2","volume":"17","author":"CH Yeh","year":"2018","unstructured":"Yeh CH, Bellon M, Nicot C. FBXW7: a critical tumor suppressor of human cancers. Mol Cancer. 2018;17:115.","journal-title":"Mol Cancer"},{"key":"6406_CR33","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s00535-015-1101-0","volume":"51","author":"Y Ye","year":"2016","unstructured":"Ye Y, Ge YM, Xiao MM, Guo LM, Li Q, Hao JQ, et al. Suppression of SHIP2 contributes to tumorigenesis and proliferation of gastric cancer cells via activation of Akt. J Gastroenterol. 2016;51:230\u201340.","journal-title":"J Gastroenterol"},{"key":"6406_CR34","doi-asserted-by":"publisher","first-page":"7725","DOI":"10.2147\/OTT.S185803","volume":"11","author":"YL Zhou","year":"2018","unstructured":"Zhou YL, Zheng C, Chen YT, Chen XM. Underexpression of INPPL1 is associated with aggressive clinicopathologic characteristics in papillary thyroid carcinoma. Onco Targets Ther. 2018;11:7725\u201331.","journal-title":"Onco Targets Ther"},{"key":"6406_CR35","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.18632\/oncotarget.26682","volume":"10","author":"S Tretbar","year":"2019","unstructured":"Tretbar S, Krausbeck P, Muller A, Friedrich M, Vaxevanis C, Bukur J, et al. TGF-beta inducible epithelial-to-mesenchymal transition in renal cell carcinoma. Oncotarget. 2019;10:1507\u201324.","journal-title":"Oncotarget"},{"key":"6406_CR36","doi-asserted-by":"publisher","first-page":"eaav5183","DOI":"10.1126\/scisignal.aav5183","volume":"12","author":"R Derynck","year":"2019","unstructured":"Derynck R, Budi EH. Specificity, versatility, and control of TGF-beta family signaling. Sci Signal. 2019;12:eaav5183.","journal-title":"Sci Signal"},{"key":"6406_CR37","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.18632\/oncotarget.13643","volume":"8","author":"S Bieerkehazhi","year":"2017","unstructured":"Bieerkehazhi S, Chen Z, Zhao Y, Yu Y, Zhang H, Vasudevan SA, et al. Novel Src\/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src\/Abl signaling. Oncotarget. 2017;8:1469\u201380.","journal-title":"Oncotarget"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06406-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06406-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06406-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T16:06:07Z","timestamp":1704989167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06406-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,11]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["6406"],"URL":"https:\/\/doi.org\/10.1038\/s41419-023-06406-7","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,11]]},"assertion":[{"value":"14 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All the mouse experiments were approved by the Animal Care and Use Committee of the University of Macau (Approval no. UMARE-015-2019). All surgical procedures strictly followed the requirements of the Animal Care and Use Committee of the Faculty of Health Sciences at the University of Macau.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"34"}}